Agilent Technologies Inc (A) Holdings Raised by Marshall Wace LLP

Marshall Wace LLP boosted its holdings in shares of Agilent Technologies Inc (NYSE:A) by 170.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,649,502 shares of the medical research company’s stock after buying an additional 1,668,360 shares during the period. Agilent Technologies comprises 1.6% of Marshall Wace LLP’s portfolio, making the stock its 2nd largest holding. Marshall Wace LLP owned approximately 0.83% of Agilent Technologies worth $186,896,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of A. Fiera Capital Corp acquired a new stake in Agilent Technologies during the second quarter worth $565,000. Virginia Retirement Systems ET AL acquired a new stake in shares of Agilent Technologies in the 2nd quarter valued at $359,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in shares of Agilent Technologies in the 2nd quarter valued at $2,071,000. Meridian Management Co. acquired a new stake in shares of Agilent Technologies in the 2nd quarter valued at $1,531,000. Finally, Sei Investments Co. boosted its stake in shares of Agilent Technologies by 42.3% in the 2nd quarter. Sei Investments Co. now owns 136,141 shares of the medical research company’s stock valued at $8,419,000 after purchasing an additional 40,462 shares in the last quarter.

Shares of Agilent Technologies stock traded down $1.00 during trading on Thursday, reaching $71.91. The company’s stock had a trading volume of 3,505,911 shares, compared to its average volume of 2,609,110. The company has a quick ratio of 2.74, a current ratio of 3.29 and a debt-to-equity ratio of 0.39. Agilent Technologies Inc has a one year low of $60.42 and a one year high of $75.11. The stock has a market capitalization of $23.24 billion, a price-to-earnings ratio of 25.77, a P/E/G ratio of 2.04 and a beta of 1.36.

Agilent Technologies (NYSE:A) last released its quarterly earnings results on Monday, November 19th. The medical research company reported $0.81 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.07. The business had revenue of $1.29 billion during the quarter, compared to analysts’ expectations of $1.26 billion. Agilent Technologies had a return on equity of 19.84% and a net margin of 6.43%. The firm’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same period in the previous year, the business posted $0.67 earnings per share. As a group, sell-side analysts anticipate that Agilent Technologies Inc will post 3.04 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 23rd. Shareholders of record on Monday, December 31st will be issued a dividend of $0.164 per share. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.15. This represents a $0.66 annualized dividend and a yield of 0.91%. The ex-dividend date is Friday, December 28th. Agilent Technologies’s payout ratio is currently 21.51%.

Agilent Technologies announced that its Board of Directors has approved a share repurchase plan on Monday, November 19th that authorizes the company to repurchase $1.75 billion in shares. This repurchase authorization authorizes the medical research company to purchase up to 8.8% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s board of directors believes its stock is undervalued.

A has been the topic of several recent analyst reports. Morgan Stanley boosted their target price on shares of Agilent Technologies from $84.00 to $86.00 and gave the company an “overweight” rating in a research note on Wednesday, October 10th. Goldman Sachs Group restated a “buy” rating and issued a $82.00 target price (up previously from $77.00) on shares of Agilent Technologies in a research note on Tuesday, September 18th. Cleveland Research downgraded shares of Agilent Technologies from a “buy” rating to a “neutral” rating in a research note on Monday, November 12th. ValuEngine upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research note on Thursday, September 13th. Finally, Zacks Investment Research downgraded shares of Agilent Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, October 16th. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Agilent Technologies has a consensus rating of “Buy” and a consensus price target of $78.75.

In other news, CEO Michael R. Mcmullen sold 15,923 shares of the company’s stock in a transaction dated Monday, December 3rd. The stock was sold at an average price of $73.20, for a total value of $1,165,563.60. Following the completion of the sale, the chief executive officer now directly owns 492,546 shares of the company’s stock, valued at approximately $36,054,367.20. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Rodney Gonsalves sold 1,500 shares of the company’s stock in a transaction dated Wednesday, November 28th. The shares were sold at an average price of $71.06, for a total value of $106,590.00. The disclosure for this sale can be found here. Insiders have sold a total of 34,683 shares of company stock valued at $2,499,491 over the last three months.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; microfluidics based automated electrophoresis products; cell analysis plate based assays; laboratory software and informatics systems; laboratory automation; dissolution testing; vacuum pumps; and measurement technologies.

Featured Article: Cost of Capital Explained

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with's FREE daily email newsletter.

Leave a Reply